Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 1
2004 1
2005 1
2008 1
2010 2
2011 2
2012 2
2013 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Rituximab for the treatment of acute exacerbation of interstitial lung disease associated with connective tissue disease.
León Román F, Pintado-Cort B, García-Casado D, Muñiz-González F, López García-Asenjo JA, Díaz-Rodríguez C, Montoro-López MN, Loucel-Bellino M, Recio-Moreno B, Rebollo-Garrido S, Martínez-Hernández Y, Cusacovich I. León Román F, et al. Among authors: lopez garcia asenjo ja. RMD Open. 2023 Sep;9(3):e003479. doi: 10.1136/rmdopen-2023-003479. RMD Open. 2023. PMID: 37673443 Free PMC article.
Assessment of Topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization.
Romero A, Martín M, Cheang MC, López García-Asenjo JA, Oliva B, He X, de la Hoya M, García Sáenz JÁ, Arroyo Fernández M, Díaz Rubio E, Perou CM, Caldés Llopis T. Romero A, et al. Among authors: lopez garcia asenjo ja. Am J Pathol. 2011 Apr;178(4):1453-60. doi: 10.1016/j.ajpath.2010.12.042. Am J Pathol. 2011. PMID: 21435434 Free PMC article. Review.
Adjuvant docetaxel for high-risk, node-negative breast cancer.
Martín M, Seguí MA, Antón A, Ruiz A, Ramos M, Adrover E, Aranda I, Rodríguez-Lescure A, Grosse R, Calvo L, Barnadas A, Isla D, Martinez del Prado P, Ruiz Borrego M, Zaluski J, Arcusa A, Muñoz M, López Vega JM, Mel JR, Munarriz B, Llorca C, Jara C, Alba E, Florián J, Li J, López García-Asenjo JA, Sáez A, Rios MJ, Almenar S, Peiró G, Lluch A; GEICAM 9805 Investigators. Martín M, et al. Among authors: lopez garcia asenjo ja. N Engl J Med. 2010 Dec 2;363(23):2200-10. doi: 10.1056/NEJMoa0910320. N Engl J Med. 2010. PMID: 21121833 Free article. Clinical Trial.
Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study.
Ikenberg H, Bergeron C, Schmidt D, Griesser H, Alameda F, Angeloni C, Bogers J, Dachez R, Denton K, Hariri J, Keller T, von Knebel Doeberitz M, Neumann HH, Puig-Tintore LM, Sideri M, Rehm S, Ridder R; PALMS Study Group. Ikenberg H, et al. J Natl Cancer Inst. 2013 Oct 16;105(20):1550-7. doi: 10.1093/jnci/djt235. Epub 2013 Oct 4. J Natl Cancer Inst. 2013. PMID: 24096620 Free PMC article.
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munárriz B, Rodríguez CA, Crespo C, de Alava E, López García-Asenjo JA, Guitián MD, Almenar S, González-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Seguí MA, Mayordomo JI, Antón A, Baena JM, Plazaola A, Modolell A, Pelegrí A, Mel JR, Aranda E, Adrover E, Alvarez JV, García Puche JL, Sánchez-Rovira P, Gonzalez S, López-Vega JM; GEICAM 9906 Study Investigators. Martín M, et al. Among authors: lopez garcia asenjo ja. J Natl Cancer Inst. 2008 Jun 4;100(11):805-14. doi: 10.1093/jnci/djn151. Epub 2008 May 27. J Natl Cancer Inst. 2008. PMID: 18505968 Free article. Clinical Trial.
Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer.
Martin M, Romero A, Cheang MC, López García-Asenjo JA, García-Saenz JA, Oliva B, Román JM, He X, Casado A, de la Torre J, Furio V, Puente J, Caldés T, Vidart JA, Lopez-Tarruella S, Diaz-Rubio E, Perou CM. Martin M, et al. Among authors: lopez garcia asenjo ja. Breast Cancer Res Treat. 2011 Jul;128(1):127-36. doi: 10.1007/s10549-011-1461-y. Epub 2011 Apr 5. Breast Cancer Res Treat. 2011. PMID: 21465170 Clinical Trial.
Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study.
Alba E, Calvo L, Albanell J, De la Haba JR, Arcusa Lanza A, Chacon JI, Sanchez-Rovira P, Plazaola A, Lopez Garcia-Asenjo JA, Bermejo B, Carrasco E, Lluch A; GEICAM. Alba E, et al. Among authors: lopez garcia asenjo ja. Ann Oncol. 2012 Dec;23(12):3069-3074. doi: 10.1093/annonc/mds132. Epub 2012 Jun 6. Ann Oncol. 2012. PMID: 22674146 Free article. Clinical Trial.
Pinning of tumoral growth by enhancement of the immune response.
Brú A, Albertos S, López García-Asenjo JA, Brú I. Brú A, et al. Among authors: lopez garcia asenjo ja. Phys Rev Lett. 2004 Jun 11;92(23):238101. doi: 10.1103/PhysRevLett.92.238101. Epub 2004 Jun 7. Phys Rev Lett. 2004. PMID: 15245196 Free article.
13 results